MedTrace Logo

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-12-11

No results posted yet for this study

Summary

This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

Conditions

  • Sarcoma
  • Castrate Resistant Prostate Cancer
  • Hormone Receptor Positive HER2 Negative Breast Cancer
  • Non-small Cell Lung Cancer
  • Solid Tumors With Known MYC Amplification

Interventions

DRUG

PRT2527

PRT2527 will be administered by intravenous infusion

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-14
Primary Completion
2023-12-06
Completion
2023-12-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05159518 on ClinicalTrials.gov